1 Introduction Pancreatic ductal adenocarcinoma (PDAC) is one of the highly aggressive types of cancer, with an overall 5-year survival rate of approximately 10% [1, 2]. Only 20% of PDAC patients are eligible for curative surgical resection at the time of diagnosis, and within 2 years after curative resection, the recurrence rate reaches 80% [3-6]. However, the rate of receiving adjuvant treatment after surgery is only 50% due to surgical complications and diminished performance status [7-9].